Cargando…

A low‐intensity 10‐min resistance exercise program that ameliorated hepatic fibrosis indices and altered G‐CSF/IP‐10/PDGF‐BB in a patient with nonalcoholic fatty liver disease: A case report

We developed a low‐intensity 10‐min resistance exercise program for nonalcoholic fatty liver disease (NAFLD). We report a case of NAFLD with elevated hepatic fibrosis indices, which were improved by a 60‐week daily exercise program. A 71‐year‐old female patient with NAFLD whose hepatic fibrosis stag...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashida, Ryuki, Nakano, Dan, Matsuse, Hiroo, Yoshio, Sachiyo, Tsutsumi, Tsubasa, Kawaguchi, Machiko, Koya, Shunji, Hirota, Keisuke, Tajima, Hiroshi, Sumida, Yoshio, Kanto, Tatsuya, Kawaguchi, Takumi, Hiraoka, Koji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037032/
https://www.ncbi.nlm.nih.gov/pubmed/36968574
http://dx.doi.org/10.1002/jgh3.12876
Descripción
Sumario:We developed a low‐intensity 10‐min resistance exercise program for nonalcoholic fatty liver disease (NAFLD). We report a case of NAFLD with elevated hepatic fibrosis indices, which were improved by a 60‐week daily exercise program. A 71‐year‐old female patient with NAFLD whose hepatic fibrosis stage corresponded to F2 was referred to our hospital. She performed the exercise once a day with no changes in other lifestyle habits and medications. The homeostasis model assessment‐insulin resistance value and NAFLD‐liver fat score, the Hepamet fibrosis score, and the enhanced liver fibrosis score decreased. The FIB‐4 index and serum levels of Mac‐2 binding protein glycosylation isomer decreased to the reference values. We investigated the changes in chemokines/cytokines. The serum granulocyte‐colony stimulating factor level was increased, and serum interferon‐gamma‐induced protein‐10 and platelet‐derived growth factor‐BB levels were decreased. Our program may be beneficial for improving hepatic fibrosis in patients with NAFLD.